166 related articles for article (PubMed ID: 16988583)
1. Sorafenib.
Hahn O; Stadler W
Curr Opin Oncol; 2006 Nov; 18(6):615-21. PubMed ID: 16988583
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in renal cell carcinoma.
Flaherty KT
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
[TBL] [Abstract][Full Text] [Related]
3. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib: delivering a targeted drug to the right targets.
Flaherty KT
Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
[TBL] [Abstract][Full Text] [Related]
8. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Ratain MJ; Eisen T; Stadler WM; Flaherty KT; Kaye SB; Rosner GL; Gore M; Desai AA; Patnaik A; Xiong HQ; Rowinsky E; Abbruzzese JL; Xia C; Simantov R; Schwartz B; O'Dwyer PJ
J Clin Oncol; 2006 Jun; 24(16):2505-12. PubMed ID: 16636341
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP
J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience.
Rey PM; Villavicencio H
Oncology; 2008; 74(3-4):245-6. PubMed ID: 18716419
[TBL] [Abstract][Full Text] [Related]
11. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
12. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib: new drug. Second-line treatment of kidney cancer: better evaluated than sunitinib.
Prescrire Int; 2007 Aug; 16(90):141-3. PubMed ID: 17724834
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib tosylate in advanced kidney cancer: past, present and future.
Porta C; Paglino C; Imarisio I; Ferraris E
Anticancer Drugs; 2009 Jul; 20(6):409-15. PubMed ID: 19436197
[TBL] [Abstract][Full Text] [Related]
16. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
Egberts F; Kahler KC; Livingstone E; Hauschild A
Onkologie; 2008 Jul; 31(7):398-403. PubMed ID: 18596389
[TBL] [Abstract][Full Text] [Related]
17. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
Dal Lago L; D'Hondt V; Awada A
Oncologist; 2008 Aug; 13(8):845-58. PubMed ID: 18695262
[TBL] [Abstract][Full Text] [Related]
18. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
19. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
Bianchi G; Loibl S; Zamagni C; Salvagni S; Raab G; Siena S; Laferriere N; Peña C; Lathia C; Bergamini L; Gianni L
Anticancer Drugs; 2009 Aug; 20(7):616-24. PubMed ID: 19739318
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
Hutson TE
Expert Rev Anticancer Ther; 2007 Sep; 7(9):1193-202. PubMed ID: 17892420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]